 | | Vol. 10.26 – 6 July, 2022 |
| |
|
|
| Investigators designed mosaic nanoparticles presenting randomly-arranged sarbecovirus spike receptor-binding domains (RBDs) to elicit antibodies against epitopes that were conserved and relatively occluded, rather than variable, immunodominant, and exposed.
[Science] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Researchers characterized the antibody profile after Ad26.COV2.S, mRNA-1273, or BNT162b2 vaccination in 158 pregnant individuals and evaluated transplacental antibody transfer by profiling maternal and umbilical cord blood in 175 maternal-neonatal dyads.
[Nature Communications] |
|
|
|
| The authors examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBD-specific memory B cells one and a half or six months after vaccination.
[Journal of Experimental Medicine] |
|
|
|
| Scientists characterized the neuropathological changes in patients with coronavirus disease 2019 and determined the underlying pathophysiological mechanisms.
[Brain] |
|
|
|
| The authors used reconstituted primary bronchial epithelia from adult and child donors to follow the SARS-CoV-2 infection dynamics.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Researchers evaluated the range and kinetics of the primary antibody response to SARS-CoV-2 mRNA-based vaccination in parallel with the B cells that are involved in generating and maintaining this response.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators presented a panel of nanobodies that could detect the spike proteins of five SARS-CoV-2 variants of concern, including Omicron.
[Communications Biology] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| The authors described the generation of a live attenuated influenza A virus vaccine using proteolysis-targeting chimeric technology to degrade viral proteins via the endogenous ubiquitin–proteasome system of host cells.
[Nature Biotechnology] |
|
|
|
| Using several mouse models and a marker to unambiguously track fetal monocyte–derived–alveolar macrophages (AM) and bone marrow monocyte–derived-AM, scientists established the kinetics and extent of replenishment and their function to recurrent influenza A virus infection.
[Science Immunology] |
|
|
|
| Researchers found that some filaments of E. coli UTI89 released from infected cells grew very rapidly and by more than 100 μm before initiating division, whereas others did not survive, suggesting that infection-related filamentation was a stress response that promoted bacterial dispersal.
[Nature Communications] |
|
|
|
| The authors developed the immune-enhancing O PA2-C3d and A22-C3d FMD vaccine strains that could stimulate receptors on the surface of B cells by inserting C3d into the VP1 region of O PA2 and A22.
[NPJ Vaccines] |
|
|
|
| Researchers compared CCR5 expression on immune cells between people living with HIV using combination antiretroviral therapy and HIV-uninfected controls, related CCR5 expression to viral reservoir size and assessed determinants of CCR5 expression.
[Scientific Reports] |
|
|
|
|
| Investigators review how recent studies on human challenge infections, self-infected individuals, travelers, and endemic populations have improved our understanding of human type 2 immunity and its effects on the microbiome.
[Mucosal Immunology] |
|
|
|
| The authors provide a comprehensive overview of mRNA vaccines and summarize their application in the fight against emerging viral diseases with particular emphasis on COVID-19 mRNA platforms.
[NPJ Vaccines] |
|
|
|
|
| The Coalition for Epidemic Preparedness Innovations (CEPI) and Codiak BioSciences announced the latest funding award under CEPI’s US $200M program to advance the development of vaccines that provide broad protection against SARS-CoV-2 and other Betacoronaviruses.
[Codiak BioSciences] |
|
|
|
| After two days of deliberation, an advisory panel convened by the World Health Organization (WHO) has concluded the monkeypox outbreak that has spread to more than 50 countries does not yet warrant the declaration of a Public Health Emergency of International Concern, its highest alert level.
[Science Insider] |
|
|
|
|
| September 11 – 16, 2022
Ventura, California, United States |
|
|
|
|
|
| | Georgia Institute of Technology – Atlanta, Georgia, United States |
|
|
|
| | The Pirbright Institute – Surrey, England, United Kingdom |
|
|
|
| | University of Copenhagen – Copenhagen, Denmark |
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
| | Boston Children’s Hospital – Boston, Massachusetts, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
